Ribociclib
Top View
- Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows
- Pan-Canadian Oncology Drug Review Final Clinical Guidance Report
- Ribociclib (LEE011)
- Addressing Challenges in Access to Oncology Medicines
- FDA-Approved Drugs Under Investigation in Multiple Myeloma for Actionable Targets
- 5.01.540 Miscellaneous Oncology Drugs
- Kisqali) for Advanced Or Metastatic Breast Cancer
- 1 NCCP Technology Review Committee (TRC) Meeting Notes
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Addressing Challenges in Access to Oncology Medicines
- Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer
- Stromal Senescence by Prolonged CDK4/6 Inhibition Potentiates Tumor Growth Xiangnan Guan1, Kyle M
- A Phase 1B/2 Study of the Oral CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer
- 2021 Multi-Tier Basic Drug List I How to Use This List Generic Drugs Are Shown in Lower-Case Boldface Type
- Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- A New Paradigm for Neoadjuvant Endocrine Therapy
- Adjuvant Abemaciclib‑Induced Pneumonitis: a Case Report and Review of the Literature